Perseus Proteomics Inc

Perseus Proteomics Inc has a strong liquidity position, with cash and equivalents amounting to ¥15.41 billion, representing 91.1% of total assets. The company has no long-term debt and a current ratio of 12.8, indicating a robust short-term liquidity profile. However, the company has negative operating cash flow of ¥833.9 million and capital expenditures of ¥158.97 million, suggesting ongoing investment in operations.

The company's profitability is currently negative, with a net loss of ¥20.47 billion and an operating loss of ¥21.22 billion. Return on equity is -14.64%, and return on assets is -12.09%, both significantly below industry norms for biotechnology firms. Gross profit of ¥2.24 billion represents 77.8% of revenue, but this is insufficient to offset operating expenses.

Perseus Proteomics Inc operates as a single business segment, with all revenue derived from its proteomics diagnostic tests. The company's geographic exposure is not disclosed in the available data, but as a Japanese-listed company, it is likely to have a significant domestic presence. No information is available on revenue concentration by geography or customer.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The current fiscal year outlook does not include numeric deltas for revenue or earnings. The company's operating losses and negative cash flow suggest a focus on R&D and market expansion rather than immediate profitability.

Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no long-term debt and a strong cash position. However, the significant net loss and negative cash flow raise concerns about long-term sustainability. No dilution potential is indicated in the basic financials, and no adjustments have been applied to the valuation metrics.

Recent events include analyst estimates with a mean price target of ¥750.00, significantly higher than the current market price of ¥166.00. The mean recommendation is 2.00 (Buy), with one Buy rating and no Strong Buy or Hold ratings. No specific filings or transcripts are available in the provided data.

Revenue grew 19.9% year-over-year to 120.4 million JPY in fiscal 2025, demonstrating consistent top-line expansion.

The company maintains zero long-term debt, placing its leverage ratio in the top quartile of the pharmaceutical cohort.

Analysts project a 410.2% upside to a target price of 750 JPY, signaling strong market confidence.

Cash conversion metrics rank as best-in-class within the pharmaceutical cohort, indicating efficient capital utilization relative to peers.

Gross profit increased to 104.1 million JPY in fiscal 2025, showing improvement in core production profitability.

The company recorded a net loss of 1.1 billion JPY in fiscal 2024, highlighting persistent unprofitability.

Free cash flow deteriorated to negative 1.26 billion JPY in fiscal 2024, indicating significant cash burn.

Operating and net margins fall in the bottom quartile of the pharmaceutical cohort, reflecting poor profitability.

Return on equity stands at negative 14.64%, ranking in the bottom quartile among pharmaceutical peers.

The company faces high credit risk, suggesting potential difficulties in meeting financial obligations or securing financing.

Revenue ¥42.1M, +78,0% YoY; Operating income +18,1% YoY.

• ▍Revenue ¥42.1M, +78,0% YoY
• ▍Operating income +18,1% YoY
• ▍Net income +15,4% YoY
• ▍Net margin -399.6%

Revenue ¥37.5M, −2,7% YoY; Operating income +17,8% YoY.

• ▍Revenue ¥37.5M, −2,7% YoY
• ▍Operating income +17,8% YoY
• ▍Net income +26,4% YoY
• ▍Net margin -542.3%

Revenue ¥23.5M, +12,5% YoY; Operating income +1,4% YoY.

• ▍Revenue ¥23.5M, +12,5% YoY
• ▍Operating income +1,4% YoY
• ▍Net income +19,7% YoY
• ▍Net margin -750.1%

Revenue ¥37.3M, +29,9% YoY; Operating income +5,5% YoY.

• ▍Revenue ¥37.3M, +29,9% YoY
• ▍Operating income +5,5% YoY
• ▍Net income −2,7% YoY
• ▍Net margin -563.8%

Revenue ¥23.7M; Operating income -¥217.1M.

• ▍Revenue ¥23.7M
• ▍Operating income -¥217.1M
• ▍Net margin -840.5%

Revenue ¥38.5M; Operating income -¥255.7M.

• ▍Revenue ¥38.5M
• ▍Operating income -¥255.7M
• ▍Net margin -717.1%

Revenue ¥20.9M; Operating income -¥225.7M.

• ▍Revenue ¥20.9M
• ▍Operating income -¥225.7M
• ▍Net margin -1050.6%

Revenue ¥28.7M; Operating income -¥212.2M.

• ▍Revenue ¥28.7M
• ▍Operating income -¥212.2M
• ▍Net margin -713.0%

Revenue ¥120.4M, +19,9% YoY; Operating income +19,6% YoY.

• ▍Revenue ¥120.4M, +19,9% YoY
• ▍Operating income +19,6% YoY
• ▍Net income +18,1% YoY
• ▍Free cash flow +22,4% YoY
• ▍Net margin -751.7%

Revenue ¥100.4M, +6,6% YoY; Operating income −40,9% YoY.

• ▍Revenue ¥100.4M, +6,6% YoY
• ▍Operating income −40,9% YoY
• ▍Net income −40,3% YoY
• ▍Free cash flow −32,4% YoY
• ▍Net margin -1100.0%

Revenue ¥94.2M, +31,0% YoY; Operating income −35,0% YoY.

• ▍Revenue ¥94.2M, +31,0% YoY
• ▍Operating income −35,0% YoY
• ▍Net income −31,4% YoY
• ▍Free cash flow −51,1% YoY
• ▍Net margin -835.4%

Revenue ¥71.9M, +5,9% YoY; Operating income −42,3% YoY.

• ▍Revenue ¥71.9M, +5,9% YoY
• ▍Operating income −42,3% YoY
• ▍Net income −45,0% YoY
• ▍Free cash flow −51,4% YoY
• ▍Net margin -832.8%